2021
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
Sposito A, Breder I, Soares A, Kimura-Medorima S, Munhoz D, Cintra R, Bonilha I, Oliveira D, Breder J, Cavalcante P, Moreira C, Moura F, de Lima-Junior J, do Carmo H, Barreto J, Nadruz W, Carvalho L, Quinaglia T. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovascular Diabetology 2021, 20: 74. PMID: 33771149, PMCID: PMC8004411, DOI: 10.1186/s12933-021-01264-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBenzhydryl CompoundsBiomarkersBlood GlucoseBrazilCarotid Artery DiseasesDiabetes Mellitus, Type 2Drug Therapy, CombinationEndothelium, VascularFemaleGlucosidesGlyburideGlycated HemoglobinHumansMaleMetforminMiddle AgedProspective StudiesSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeVasodilationConceptsFlow-mediated dilationSodium-glucose cotransporter-2 inhibitorsCoprimary endpointsAtherosclerotic diseaseWeeks of therapyResultsNinety-seven patientsMacrovascular endothelial functionCotransporter-2 inhibitorsType 2 diabetes mellitusRandomized active-controlled trialActive-controlled trialCarotid intima-media thicknessRandomized clinical trialsIntima-media thicknessDapagliflozin EffectGlibenclamide armsDapagliflozin groupArterial wall functionOpen-labelSGLT2i treatmentGlibenclamide groupResultsNinety-sevenSingle-centerMedian HbA1cCarotid atherosclerotic disease
2020
A current review of COVID-19 for the cardiovascular specialist
Lang J, Wang X, Moura F, Siddiqi H, Morrow D, Bohula E. A current review of COVID-19 for the cardiovascular specialist. American Heart Journal 2020, 226: 29-44. PMID: 32497913, PMCID: PMC7252118, DOI: 10.1016/j.ahj.2020.04.025.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine MonophosphateAlanineAntimalarialsAntiviral AgentsBetacoronavirusBiomarkersCardiovascular DiseasesChloroquineCoronavirus InfectionsCOVID-19HumansHydroxychloroquineHypoxiaPandemicsPlasmaPneumonia, ViralReceptor, Angiotensin, Type 2Risk FactorsSARS-CoV-2Takotsubo CardiomyopathyVirus InternalizationConceptsAcute cardiac injuryCardiac injuryAdverse outcomesLevels of cardiac troponinAssociated with adverse outcomesHyperinflammatory cytokine stormType 2 myocardial infarctionPre-existing cardiovascular diseaseLevel of suspicionComplications of COVID-19Stress-related cardiomyopathyIncreased blood levelsCardiovascular risk factorsNonischemic myocardial injurySevere COVID-19Cardiovascular complications of COVID-19Nonischemic causesTakotsubo syndromeNatriuretic peptideD-dimerHigher mortality riskCardiovascular complicationsDiffuse thrombosisInflammatory milieuMyocardial dysfunction
2019
Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity
de Lima-Junior J, Virginio V, Moura F, Bertolami A, Bertolami M, Coelho-Filho O, Zanotti I, Nadruz W, de Faria E, de Carvalho L, Sposito A. Excess weight mediates changes in HDL pool that reduce cholesterol efflux capacity and increase antioxidant activity. Nutrition Metabolism And Cardiovascular Diseases 2019, 30: 254-264. PMID: 31753789, DOI: 10.1016/j.numecd.2019.09.017.Peer-Reviewed Original ResearchConceptsCarotid intima-media thicknessBody mass indexCholesterol efflux capacityReduced cholesterol efflux capacityNon-diabetic individualsNon-obeseHDL-CIncreased values of BMIAtherosclerotic burdenEfflux capacityValues of body mass indexElevation of body mass indexProtective function of HDLIncreased BMIObesity-related declineInhibition of platelet aggregationHigh-density lipoprotein (HDLIncreased atherosclerotic burdenAssociated with carotid intima-media thicknessIncreased HDL-CDecreased HDL concentrationIntima-media thicknessFunction of HDLLipoprotein (HDLPlatelet aggregation inhibitionOmega-3 intake is associated with attenuated inflammatory response and cardiac remodeling after myocardial infarction
Campos-Staffico A, Costa A, Carvalho L, Moura F, Santos S, Coelho-Filho O, Nadruz W, Quinaglia e Silva J, Sposito A. Omega-3 intake is associated with attenuated inflammatory response and cardiac remodeling after myocardial infarction. Nutrition Journal 2019, 18: 29. PMID: 31060562, PMCID: PMC6503367, DOI: 10.1186/s12937-019-0455-1.Peer-Reviewed Original ResearchConceptsCardiac magnetic resonance imagingAcute inflammatory responseCardiac remodelingInflammatory responseAssociated with attenuated inflammatory responsesLeft ventricle ejection fractionBrain-type natriuretic peptideHs-C-reactive proteinFood frequency questionnaireEnd-diastolic volumeReduced daily intakeLeft ventricular remodelingOmega-3 intakeLeft ventricle end-diastolic volumeOmega-3 polyunsaturated fatty acidsExcessive inflammatory responseAssociated with attenuationAnti-inflammatory effectsMagnetic resonance imagingFrequency questionnaireEjection fractionNatriuretic peptideResultsThe intakeInflammatory markersVentricular remodeling
2013
Impact of Seasonality on the Prevalence of Dyslipidemia: A Large Population Study
Moura F, Dutra-Rodrigues M, Cassol A, Parra E, Zago V, Panzoldo N, Alexandre F, Vieira I, Vendrame F, Virginio V, Castanho V, Danelon M, Nunes V, Leança C, Saraiva F, Coelho O, Nakandakare E, Quintão E, de Faria E, Sposito A. Impact of Seasonality on the Prevalence of Dyslipidemia: A Large Population Study. Chronobiology International 2013, 30: 1011-1015. PMID: 23837747, DOI: 10.3109/07420528.2013.793698.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge DistributionAge FactorsAgedAged, 80 and overBiomarkersBrazilChildChild, PreschoolCholesterol, HDLCholesterol, LDLCross-Sectional StudiesDyslipidemiasFemaleHumansInfantInfant, NewbornMaleMiddle AgedNonlinear DynamicsPeriodicityPrevalenceRisk FactorsSeasonsSex DistributionSex FactorsTime FactorsTriglyceridesYoung AdultConceptsLDL-CHDL-CLipoprotein cholesterolLipid profileLow-density lipoprotein cholesterolPlasma low-density lipoprotein cholesterolHigh-density lipoprotein cholesterolPrevalence of dyslipidemiaAnalysis of relative riskLipid profile parametersVariation of lipid profilePrimary care centersLipid parametersRate of goal achievementCross-sectional analysisConsecutive individualsRelative riskCardiovascular diseaseCare centerHealth checkupsMiddle-aged adultsTriglyceridesBiological rhythmsPreliminary dataPrevalence
2011
High plasma HDL-C attenuates stress hyperglycemia during acute phase of myocardial infarction
Carvalho L, Cintra R, Moura F, Martins N, Quinaglia e Silva J, Coelho O, Sposito A, Group O. High plasma HDL-C attenuates stress hyperglycemia during acute phase of myocardial infarction. Atherosclerosis 2011, 220: 231-236. PMID: 22018645, DOI: 10.1016/j.atherosclerosis.2011.09.044.Peer-Reviewed Original ResearchConceptsHDL-C levelsHDL-C quartilePlasma HDL-C levelsHDL-CC-peptideMyocardial infarctionAcute phaseStress hyperglycemiaInsulin sensitivityAssociated with HDL-C levelsConsecutive non-diabetic patientsNon-diabetic patientsAcute phase of MILow plasma HDL-C levelsAcute phase of myocardial infarctionST-segment elevationPhase of myocardial infarctionBeta-cell functionAssess insulin sensitivityPhase of MIImproved insulin sensitivityBlood glucose changesPlasma glucoseQuartilePlasma insulin